Can I get retatrutide through expanded access?

It is not a route individuals can pursue directly. Expanded access requires a treating physician's request, sponsor agreement, and regulatory oversight, for patients meeting defined criteria.

Does an expanded access listing mean approval is close?

No. It is a separate mechanism from approval and says nothing about the timing of any regulatory decision.

Why does it show on ClinicalTrials.gov without a phase?

Because it is not a trial. Nothing is being measured, so there is no phase, enrolment target or outcome measure.

Retatrutide Expanded Access: What It Actually Is

The short answer

ClinicalTrials.gov lists a pre-approval expanded access record for retatrutide (NCT07629401) with a status of available. Expanded access is a regulated route by which a sponsor may supply an unapproved medicine to specific patients outside a trial, through their physician. It is not a purchase route and not a general availability signal.

Key facts

Registration: NCT07629401
Type: Pre-approval expanded access
Status: Available
Sponsor: Eli Lilly and Company
Not a: Clinical trial (no phase, no endpoints)
Access route: Through a treating physician to the sponsor
Regulatory status: Retatrutide remains unapproved

What expanded access is

Expanded access, sometimes called compassionate use, is a regulated pathway allowing a patient with a serious condition to receive an investigational medicine outside a clinical trial. It requires a treating physician to request it, the sponsor to agree to supply, and regulatory and ethics oversight. It exists for patients who cannot enrol in a trial and have no satisfactory alternative.

Why it appears on a trials registry at all

ClinicalTrials.gov records expanded access programmes alongside trials, but they are a different kind of record, no phase, no enrolment target, no primary outcome measure, because nothing is being measured. The status field reads available rather than recruiting. Seeing it in a search for retatrutide trials and reading it as another study is an easy mistake.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

What it does not mean

It does not mean retatrutide is approved, approaching approval, or generally obtainable. It does not create a supply route for anyone outside the defined pathway, and it is not something an individual can apply to directly. The compound remains investigational in every jurisdiction, and its regulatory status is unchanged by the existence of this record.

Why it still matters

Expanded access records get cited in discussion as evidence that a compound is becoming available. It is a reasonable-sounding inference and it is wrong. The programme is a narrow clinical mechanism operating under sponsor and regulator control, and conflating it with availability is the sort of error that propagates quickly once someone makes it.

The distinction that matters here

Material supplied for laboratory research is not connected to this programme in any way. It is not the same supply, not an alternative to it, and not a route into it. Research material is supplied for laboratory use only, and nothing about an expanded access listing changes that.

Frequently asked questions

Can I get retatrutide through expanded access?: It is not a route individuals can pursue directly. Expanded access requires a treating physician's request, sponsor agreement, and regulatory oversight, for patients meeting defined criteria.
Does an expanded access listing mean approval is close?: No. It is a separate mechanism from approval and says nothing about the timing of any regulatory decision.
Why does it show on ClinicalTrials.gov without a phase?: Because it is not a trial. Nothing is being measured, so there is no phase, enrolment target or outcome measure.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction. That is the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer. It is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov, as the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum